Celyad Oncology SA (CYAD) Stock Price, Quote, News and Overview
NASDAQ:CYAD - Nasdaq - US1512052002 - ADR - Currency: USD
CYAD Quote, Performance and Key Statistics
NASDAQ:CYAD (5/18/2023, 8:00:00 PM)
0.47
-0.06 (-11.1%)
The current stock price of CYAD is 0.47 USD. In the past month the price decreased by -27.27%. In the past year, price decreased by -76.5%.
CYAD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CYAD
Company Profile
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 28 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).
Company Info
Celyad Oncology SA
Axis Business Park Rue Edouard Belin 2
Mont-Saint-Guibert BRABANT-WALLON 1435 BE
CEO: Filippo Petti
Employees: 28
Company Website: https://www.celyad.com/
Phone: 3210394100.0
Celyad Oncology SA / CYAD FAQ
What is the stock price of Celyad Oncology SA today?
The current stock price of CYAD is 0.47 USD. The price decreased by -11.1% in the last trading session.
What is the ticker symbol for Celyad Oncology SA stock?
The exchange symbol of Celyad Oncology SA is CYAD and it is listed on the Nasdaq exchange.
On which exchange is CYAD stock listed?
CYAD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Celyad Oncology SA stock?
10 analysts have analysed CYAD and the average price target is 0.48 USD. This implies a price increase of 1.41% is expected in the next year compared to the current price of 0.47. Check the Celyad Oncology SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Celyad Oncology SA worth?
Celyad Oncology SA (CYAD) has a market capitalization of 10.62M USD. This makes CYAD a Nano Cap stock.
How many employees does Celyad Oncology SA have?
Celyad Oncology SA (CYAD) currently has 28 employees.
What are the support and resistance levels for Celyad Oncology SA (CYAD) stock?
Celyad Oncology SA (CYAD) has a resistance level at 0.57. Check the full technical report for a detailed analysis of CYAD support and resistance levels.
Should I buy Celyad Oncology SA (CYAD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CYAD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CYAD, evaluating the profitability, health, valuation and growth aspects
- Celyad Oncology SA (CYAD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Celyad Oncology SA (CYAD) Sales and EPS estimates to see what analysts future expectations are.
- Celyad Oncology SA (CYAD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Celyad Oncology SA (CYAD) Insider and Institutional Ownership to learn about the owners and their transactions.
- Celyad Oncology SA (CYAD) Stock Chart to make your own analysis
- Celyad Oncology SA (CYAD) Latest news and press-releases to stay up to date.
Does Celyad Oncology SA (CYAD) stock pay dividends?
CYAD does not pay a dividend.
When does Celyad Oncology SA (CYAD) report earnings?
Celyad Oncology SA (CYAD) will report earnings on 2023-08-03, after the market close.
What is the Price/Earnings (PE) ratio of Celyad Oncology SA (CYAD)?
Celyad Oncology SA (CYAD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.95).
CYAD Technical Analysis
CYAD Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CYAD. CYAD may be in some trouble as it scores bad on both profitability and health.
CYAD Financial Highlights
Over the last trailing twelve months CYAD reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS decreased by -5.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.03 |
CYAD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 40% to CYAD. The Buy consensus is the average rating of analysts ratings from 10 analysts.